Lupin Ltd. Hits New 52-Week High at Rs.2249.3 Marking Significant Milestone

Stock Performance and Market Context

On 3 Feb 2026, Lupin Ltd. opened with a gap up, surging 5.67% from the previous close, signalling strong buying interest at the outset of trading. The stock touched an intraday high of Rs.2249.3, marking its highest price level in the past year. Despite this robust gain, Lupin marginally underperformed its sector, which advanced by 2.83%, with the stock’s day change recorded at 2.43%.

After two consecutive days of decline, the stock reversed its trend, demonstrating renewed investor confidence. Lupin is currently trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating a sustained upward trajectory and technical strength.

In comparison, the broader market showed mixed signals. The Sensex opened sharply higher by 3,656.74 points but later retreated by 1,258.60 points, closing at 84,064.60, down 2.94% on the day. The benchmark index remains 2.49% below its own 52-week high of 86,159.02. Notably, the Sensex is trading below its 50-day moving average, although the 50DMA remains above the 200DMA, suggesting a cautiously optimistic medium-term outlook.

Financial Metrics Underpinning the Rally

Lupin’s recent price surge is supported by solid financial fundamentals. The company maintains a low average debt-to-equity ratio of 0.10 times, reflecting prudent capital management and limited leverage. Over the long term, Lupin has demonstrated healthy growth, with net sales expanding at an annual rate of 10.57% and operating profit margins standing at a robust 37.09%.

In the September 2025 quarter, Lupin reported a Profit Before Tax excluding other income (PBT LESS OI) of Rs.1,916.97 crores, marking an impressive 82.3% increase compared to the previous four-quarter average. This surge in profitability is complemented by a high Return on Capital Employed (ROCE) of 22.22% for the half-year period, underscoring efficient utilisation of capital resources.

The company’s operating profit to interest ratio reached a peak of 21.76 times in the same quarter, highlighting strong earnings relative to interest expenses. Lupin’s Return on Equity (ROE) stands at 22%, indicating attractive returns for shareholders. Valuation metrics further support the stock’s appeal, with a price-to-book value of 4.9, trading at a discount relative to its peers’ historical averages.

Over the past year, Lupin’s stock price has appreciated by 7.48%, slightly lagging the Sensex’s 8.90% gain. However, the company’s profits have risen substantially by 64.7% during this period, resulting in a low PEG ratio of 0.4, which suggests earnings growth is not fully reflected in the current share price.

Institutional Backing and Market Position

Lupin Ltd. benefits from strong institutional ownership, with 47.08% of its shares held by institutional investors. This level of holding reflects confidence from entities with extensive analytical resources and a long-term perspective on the company’s fundamentals.

The company is also distinguished by its MarketsMojo Mojo Score of 74.0, which corresponds to a Buy grade. This rating was recently adjusted from a Strong Buy on 28 Jan 2026, reflecting a nuanced assessment of the stock’s current valuation and momentum. Lupin’s market capitalisation grade is 1, indicating its status as a large-cap stock within the Pharmaceuticals & Biotechnology sector.

Despite the sector’s overall gain of 2.83% today, Lupin’s performance remains noteworthy given its recovery after a brief dip and its ability to sustain levels above all major moving averages. The stock’s 52-week low stands at Rs.1774, highlighting the significant appreciation to the current high of Rs.2249.3.

Sector and Peer Comparison

Within the Pharmaceuticals & Biotechnology sector, Lupin Ltd. stands out for its consistent financial performance and valuation metrics. The sector has experienced a 2.83% gain today, driven by broader market optimism and sector-specific developments. Lupin’s ability to outperform the Sensex over the past year in terms of profit growth, despite a slightly lower stock price appreciation, highlights its operational efficiency and earnings quality.

The company’s PEG ratio of 0.4 is particularly notable, indicating that earnings growth is strong relative to the stock price, a factor that distinguishes Lupin from many of its peers. Its Return on Capital Employed and Return on Equity metrics are among the highest in the sector, reinforcing its position as a quality large-cap stock.

Trading at a discount to peer valuations, Lupin offers a valuation profile that is attractive for those analysing fundamentals and sector dynamics. The stock’s recent upgrade from Strong Buy to Buy by MarketsMojo reflects a balanced view of its current price momentum and valuation considerations.

Summary of Key Metrics

To summarise, Lupin Ltd.’s key financial and market metrics as of 3 Feb 2026 include:

• New 52-week high price: Rs.2249.3
• Day’s price change: +2.43%
• Opening gap up: +5.67%
• Market cap grade: 1 (Large Cap)
• Mojo Score: 74.0 (Buy grade)
• Debt to Equity ratio: 0.10 times
• Net sales growth (annual): 10.57%
• Operating profit margin: 37.09%
• PBT LESS OI (Sep 25 quarter): Rs.1,916.97 crores, +82.3%
• ROCE (Half Year): 22.22%
• Operating profit to interest ratio (quarter): 21.76 times
• ROE: 22%
• Price to Book Value: 4.9
• PEG ratio: 0.4
• Institutional holdings: 47.08%

The stock’s performance today and its new 52-week high reflect a combination of strong fundamentals, technical momentum, and sectoral tailwinds. Lupin Ltd. remains a significant presence in the Pharmaceuticals & Biotechnology space, with metrics that underscore its quality and resilience.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →